|
rs9282858
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The overall results demonstrated that SRD5A2 rs9282858 polymorphism was remarkably associated with increased susceptibility of PCa (TT vs. AA: OR = 4.08, 95% CI = 1.94-8.58; TT + AT vs. AA: OR = 1.28, 95% CI = 1.11-1.47; TT vs. AA + AT: OR = 4.44, 95% CI = 2.12-9.27; allele T vs. allele A: OR = 1.34, 95% CI = 1.17-1.54).
|
28489754 |
2017 |
|
rs523349
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Furthermore, SRD5A2 rs523349 polymorphism may be a promising biomarker for metastatic prostate cancer patients treated with primary ADT and a molecular target for advanced prostate cancer.
|
26169017 |
2015 |
|
rs523349
|
|
|
0.100 |
GeneticVariation |
BEFREE |
CYP19 1531 C>T, SRD5A2 gene V89L, CYP17 gene -34 T/C, PSA-158 (G/A) regions were evaluated for the association between polymorphisms and benign prostatic hyperplasia and prostate cancer in study population.
|
26214411 |
2015 |
|
rs523349
|
|
|
0.100 |
GeneticVariation |
BEFREE |
It was confirmed that in the population studied, the SRD5A2 V89L polymorphism was not associated with the risk of prostate cancer and SRD5A2 was not shown to be a key gene involved in prostate cancer development.
|
25310105 |
2014 |
|
rs523349
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Although there was no overall association between V89L and prostate cancer risk, A49T might play a role in the etiology of prostate cancer among Caucasians.
|
23277398 |
2013 |
|
rs9282858
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Although there was no overall association between V89L and prostate cancer risk, A49T might play a role in the etiology of prostate cancer among Caucasians.
|
23277398 |
2013 |
|
rs523349
|
|
|
0.100 |
GeneticVariation |
BEFREE |
However, no clear consensus has been reached on the association between the SRD5A2 V89L, A49T and TA repeat polymorphisms and prostate cancer (PCa) risk.
|
21177315 |
2011 |
|
rs9282858
|
|
|
0.100 |
GeneticVariation |
BEFREE |
However, no clear consensus has been reached on the association between the SRD5A2 V89L, A49T and TA repeat polymorphisms and prostate cancer (PCa) risk.
|
21177315 |
2011 |
|
rs523349
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our study suggests SRD5A2 V89L polymorphism could play a low-penetrant role in PCa risk among Europeans and individuals younger than 65 years.
|
19760631 |
2010 |
|
rs523349
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The authors found that prostate cancer was not associated with V89L (L allele vs. V allele: odds ratio = 0.99, 95% confidence interval: 0.94, 1.05) and was probably not associated with A49T (T allele vs. A allele: odds ratio = 1.10, 95% confidence interval: 0.86, 1.40).
|
19914946 |
2010 |
|
rs9282858
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The authors found that prostate cancer was not associated with V89L (L allele vs. V allele: odds ratio = 0.99, 95% confidence interval: 0.94, 1.05) and was probably not associated with A49T (T allele vs. A allele: odds ratio = 1.10, 95% confidence interval: 0.86, 1.40).
|
19914946 |
2010 |
|
rs523349
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We evaluated the relationship of two single-nucleotide polymorphisms, A49T and V89L, with prostate cancer risk in a case-control study.
|
19215786 |
2009 |
|
rs523349
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our results indicate that the SRD5A2 V89L VV genotype interacts with VDR FokI TT/CT genotypes in NHW men and VDR CDX2 GG genotypes in HW men to increase the risk for prostate cancer.
|
18483391 |
2008 |
|
rs523349
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Thirty-three men with early onset prostate cancer (PCa) were genotyped for the SRD5A2 V89L substitution and other polymorphisms in genes encoding receptors or enzymes that play important roles in pathways of steroid metabolism to ascertain if they were associated with standard clinical measures of disease progression at the time of diagnosis.
|
18780294 |
2008 |
|
rs523349
|
|
|
0.100 |
GeneticVariation |
BEFREE |
However, the absence of an overall association between V89L genotype and aggressive prostate cancer argues for a cautious interpretation of these observations.
|
18268111 |
2008 |
|
rs9282858
|
|
|
0.100 |
GeneticVariation |
BEFREE |
After evaluating more than 6000 cases and 6000 controls, there is little evidence of a role for the SRD5A2 A49T variant in prostate cancer</span> risk.
|
18469342 |
2008 |
|
rs9282858
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This study tested the interactions of VDR (CDX2, FokI) and SRD5A2 (V89L, A49T) polymorphisms, and their associations with prostate cancer.
|
18483391 |
2008 |
|
rs523349
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Controversy exists over the significance of associations between the SRD5A2 (5alpha-reductase type 2) polymorphisms, A49T and V89L, and risk of prostate cancer.
|
17136762 |
2007 |
|
rs523349
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our data confirm in a large and homogeneous Caucasian French population that the low-activity V89L variant is associated with an increased risk of aggressive prostate cancer.
|
17448593 |
2007 |
|
rs523349
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In Caucasians, the HSD3B2 (TG)n,(TA)n,(CA)n intron 3 length polymorphism is associated with both prostate cancer risk and aggressiveness and the SRD5A2 V89L polymorphism may modify the risk conferred by this polymorphism.
|
17823934 |
2007 |
|
rs9282858
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Carriers of the rarer A49T A allele were at a 60% higher risk of prostate cancer (OR = 1.60; 95% CI 1.09-2.36; p = 0.02) and 50% lower risk of vertex and frontal balding (p = 0.03) compared with men homozygous for the more common G allele.
|
17136762 |
2007 |
|
rs523349
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These observations have suggested that the CYP17 A2/A2, CYP1B1 Val/Val, and CYP2D6 genotypes may be associated with an altered risk of prostate cancer, while the CYP2D6 and SRD5A2 V89L polymorphism have no association with its risk in the North Indian population.
|
16716118 |
2006 |
|
rs523349
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The SRD5A2 polymorphisms A49T, V89L and R227Q, the androgen receptor CAG and GGN repeats and sex hormone status was investigated in men with prostate cancer (CaP) (n=89), benign prostate hyperplasia (n=45) and healthy military conscripts (n=223).
|
16039774 |
2005 |
|
rs523349
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Overall, the V89L variant was associated with prostate cancer; the OR for men with the leucine-leucine (LL) genotype compared to men with the valine-valine (VV) genotype was 4.47 (95% CI, 1.24-16.18).
|
16018939 |
2005 |
|
rs9282858
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Prostate cancer and BPH were not associated with the alanine-49 to threonine single nucleotide polymorphism and the (TA)n repeat.
|
16018939 |
2005 |